P/E ratio for Lumos Pharma (LUMO)
P/E ratio as of April 2025 (TTM): -0.9214
According to Lumos Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.921444. At the end of 2022 the company had a P/E ratio of -0.7814.
P/E ratio history for Lumos Pharma from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7814 | -59.3% |
| 2021 | -1.92 | -95.22% |
| 2020 | -40.1 | 14395.25% |
| 2019 | -0.2768 | 136.01% |
| 2018 | -0.1173 | -69.41% |
| 2017 | -0.3835 | -1.3% |
| 2016 | -0.3885 | -86.64% |
| 2015 | -2.91 | -342.37% |
| 2014 | 1.20 | -160.85% |
| 2013 | -1.97 | 59.04% |
| 2012 | -1.24 | 66.87% |
| 2011 | -0.7431 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 | 10.4 | -1,230.86% | 🇺🇸 USA |
 | -3.33 | 261.75% | Bahamas |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.